<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230208057358N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-11</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>Technical comparison of intercostal flank and subcostal flank incisions in open kidney surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Technical comparison of intercostal flank and subcostal flank incisions in open kidney surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-28</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68486</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: The studied samples will be selected as available and randomly divided into intervention groups. The samples are divided into two equal groups of intercostal flank incision (A) and subcostal flank incision (B) using the block randomization method. Our randomization tool in this study is random allocation software version 1, which is available at https://mahmoodsaghaei.tripod.com/Softwares/randalloc.html. The information required by the software, including the number of groups (2 groups), the name of each group (A=1, B=2), sample size (64 patients) and block size (4) were entered to generate a random sequence and based on that , 16 blocks of 4 including two groups A and B were randomly designed using the software.
In this study, we will use the concealment of random allocation for the purpose of concealment, which refers to the method used to perform a random sequence on the participants in the study, in such a way that the allocated group is not known before the allocation of the individual. In this method, each of the generated random sequences is recorded on a card and the cards will be placed in sealed opaque envelopes in order. In order to maintain a random sequence on the outer surface of the envelopes, numbering will be done in the same order. Finally, the lid of the letter envelopes will be glued and placed in a box. At the time of registration of participants, based on the order of entry of qualified participants into the study, one of the envelopes will be opened and the assigned group of that participant will be revealed, Blinding description: Participants will not know which surgical incision technique was used for them.</study_design>
      <phase>N/A</phase>
      <hc_freetext>open kidney surgeries; flank hernia and bulge.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Flank intercostal cut (lateral oblique cut between the 11th and 12th ribs from the rectus sheath to the sacrospinalis muscle). Intervention 2: Control group: Subcostal flank incision (diagonal flank incision that is made about 2 cm below the 12th rib from the rectus sheath to the Sacrospinalis muscle).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In this study, it will find part of the same data as the information related to the main outcome, follow-ups, and background and demographic information of the participants with the aim of researching the publication.

When:
No decision has been made yet

To whom:
The results of this study will be available for researchers working in academic and scientific institutions, surgeons, residents and nurses working in the clinical field.

Conditions:
No decision has been made yet

Where to obtain:
To receive documents or get guidance, people can access the email of the person responsible for this study at the address below.
Email address: al.abdi@edu.umsha.ac.ir

How to obtain:
No decision has been made yet

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Alireza Abdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 110, Imam Khomeini St., Maryanaj</address>
        <city>hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6514144868</zip>
        <telephone>+98 81 3426 3597</telephone>
        <email>al.abdi@edu.umsha.ac.ir</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Abdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 110, Imam Khomeini St., Maryanaj</address>
        <city>hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6514144868</zip>
        <telephone>+98 81 3426 3597</telephone>
        <email>al.abdi@edu.umsha.ac.ir</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients are candidates for open kidney surgery
Willingness and consent to participate in the study
Body mass index (BMI) between 18 and 30</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Re-operation with a cut on the previous incision
Presence of abdominal wall hernia at the same time
The person participating in the study is diabetic
Being pregnant if the person participating in the study is a woman
History of chronic obstructive pulmonary disease
History of peritoneal dialysis
History of previous hernia
History of taking immunosuppressive drugs
History of smoking and drug use
History of connective tissue diseases and disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Flank intercostal cut (lateral oblique cut between the 11th and 12th ribs from the rectus sheath to the sacrospinalis muscle)</i_keyword>
      <i_keyword>Control group: Subcostal flank incision (diagonal flank incision that is made about 2 cm below the 12th rib from the rectus sheath to the Sacrospinalis muscle)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hernia and bulge after surgery. Timepoint: At times 3 and 6 months after the operation. Method of measurement: Clinical examination by a specialist surgeon and medical imaging.</prim_outcome>
      <prim_outcome>Pain after surgery. Timepoint: in 1 and 3 months after surgery. Method of measurement: Visual analog scale (VAS).</prim_outcome>
      <prim_outcome>The amount of painkillers received. Timepoint: At the time of discharge from the hospital. Method of measurement: Injection syringe (in milliliters).</prim_outcome>
      <prim_outcome>Surgical incision scar. Timepoint: At times 3 and 6 months after the operation. Method of measurement: Manchester scar scale.</prim_outcome>
      <prim_outcome>Incision time. Timepoint: During surgery. Method of measurement: Digital clock (in minutes).</prim_outcome>
      <prim_outcome>Closure time. Timepoint: During surgery. Method of measurement: Digital clock (in minutes).</prim_outcome>
      <prim_outcome>Exposure of the operative site. Timepoint: Immediately after surgery. Method of measurement: Likert scale - scoring from one (suitable and sufficient exposure - highest satisfaction) to five (inappropriate and poor exposure - lowest satisfaction) -.</prim_outcome>
      <prim_outcome>Quality of Life. Timepoint: Once before surgery and 1 and 3 months after surgery. Method of measurement: SF-36 questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-27</approval_date>
        <contact_name>Ethics committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>Vice-chancellor for research and technology, In front of the Mardom park, Shahid Fahmideh steet, Hamadan Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
